Athanasios Makristathis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Athanasios Makristathis has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
Alexander M. Hirschl
Division of Clinical Microbiology, Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria
5 shared publications- Georg Stary
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
3 shared publications - Michael Ramharter
I. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
3 shared publications A. M. Hirschl
Division of Clinical Microbiology, Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria
2 shared publications- Alexandra Fochtmann-Frana
Department of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria
2 shared publications - André Barth
Medical University of Vienna, Clinical Division of Plastic and Reconstructive Surgery, Department of Surgery, Vienna, Austria
2 shared publications
Latest Publications
- Open Access
Associations of Diabetes Mellitus Status and Geriatric Nutritional Risk Index with the Gut Microbiota in Nursing-Home Residents
Background/Objectives: Malnutrition and diabetes mellitus (DM) have been linked to gut microbial perturbations, yet data are scarce for the aging population, especially in a nursing-home setting. As this group is generally at risk for malnutrition, we aimed to investigate the link between DM and gut microbial patterns in interaction with nutritional risk status in nursing-home residents. Methods: Stool samples were collected from 173 nursing-home residents (77.5% female, mean age 86 years) and were analyzed via 16S rRNA sequencing. Furthermore, the Geriatric Nutritional Risk Index (GNRI) was assessed and data on comorbidity status, anthropometric measurements, and medication were acquired. Results: Fifty-one residents had DM (mean HbA1c 6%). There were no DM-related differences in alpha diversity (observed richness: p = 0.733; Shannon index: p = 0.747). PERMANOVA revealed slight differences in beta diversity according to GNRI (R2 = 0.009, p = 0.032), but no significant differences when adding DM status. Differential abundance analysis showed Clostridium_Clostridiaceae, Haemophilus, Actinomycetaceae and Micrococcaceae as significantly decreased with DM, independent of age, sex, and BMI. No interaction between DM and the GNRI in microbial diversity or composition was found. Conclusions: We report malnutrition-related differences in beta diversity and diabetes-related microbial taxa differences in nursing-home residents. DM status did not influence the relationship between the GNRI and gut microbiota in this population.
Open AccessAssociations of Diabetes Mellitus Status and Geriatric Nutritional Risk Index with the Gut Microbiota in Nursing-Home Residents
Background/Objectives: Malnutrition and diabetes mellitus (DM) have been linked to gut microbial perturbations, yet data are scarce for the aging population, especially in a nursing-home setting. As this group is generally at risk for malnutrition, we aimed to investigate the link between DM and gut microbial patterns in interaction with nutritional risk status in nursing-home residents. Methods: Stool samples were collected from 173 nursing-home residents (77.5% female, mean age 86 years) and were analyzed via 16S rRNA sequencing. Furthermore, the Geriatric Nutritional Risk Index (GNRI) was assessed and data on comorbidity status, anthropometric measurements, and medication were acquired. Results: Fifty-one residents had DM (mean HbA1c 6%). There were no DM-related differences in alpha diversity (observed richness: p = 0.733; Shannon index: p = 0.747). PERMANOVA revealed slight differences in beta diversity according to GNRI (R2 = 0.009, p = 0.032), but no significant differences when adding DM status. Differential abundance analysis showed Clostridium_Clostridiaceae, Haemophilus, Actinomycetaceae and Micrococcaceae as significantly decreased with DM, independent of age, sex, and BMI. No interaction between DM and the GNRI in microbial diversity or composition was found. Conclusions: We report malnutrition-related differences in beta diversity and diabetes-related microbial taxa differences in nursing-home residents. DM status did not influence the relationship between the GNRI and gut microbiota in this population.
- Top Cited PapersOpen Access
- 6 May 2026
- Published by Springer Nature in Nature
- Vol. 655 (8121) , 1-8
Genome-wide sweeps create ecological units in the human gut microbiome
The human gut microbiome is shaped by diverse selective forces that originate from host and environmental factors and it substantially influences health and disease. Whereas the association of microbial lineages with various health conditions has been shown at different taxonomic levels 1–5 , the extent to which unifying adaptive mechanisms sort microbial lineages into ecologically differentiated populations remains poorly understood. Here we show that genome-wide selective sweeps are a pervasive mechanism that differentiates bacteria in the microbiome. This mechanism leads to population structures akin to global epidemics across geographically and ethnically diverse human populations. Such sweeps arise when an adaptation allows a clone to outcompete others in its niche followed by rediversification, and they manifest as clusters of closely related genomes on long branches in phylogenetic trees. This structure is revealed by excluding recombination events that mask the clonal descent of the genomes. Indeed, we show that genome-wide sweeps originate under a wide range of recombination rates in at least 66 taxa from 25 bacterial families. Estimated ages of divergence suggest that sweep clusters can spread globally within decades and that this process has occurred throughout human history. Sweep clusters are associated with different host conditions—such as age, colorectal cancer, inflammatory bowel diseases and type 2 diabetes—as an indication of their ecological differentiation. Our results reveal an evolutionary mechanism for the observation of stably inherited strains with differential associations and provide a theoretical foundation for analysing adaptation among microbial populations.
- 6 May 2026
- Published by Springer Nature in Nature
- Vol. 655 (8121) , 1-8
Top Cited PapersOpen AccessGenome-wide sweeps create ecological units in the human gut microbiome
The human gut microbiome is shaped by diverse selective forces that originate from host and environmental factors and it substantially influences health and disease. Whereas the association of microbial lineages with various health conditions has been shown at different taxonomic levels 1–5 , the extent to which unifying adaptive mechanisms sort microbial lineages into ecologically differentiated populations remains poorly understood. Here we show that genome-wide selective sweeps are a pervasive mechanism that differentiates bacteria in the microbiome. This mechanism leads to population structures akin to global epidemics across geographically and ethnically diverse human populations. Such sweeps arise when an adaptation allows a clone to outcompete others in its niche followed by rediversification, and they manifest as clusters of closely related genomes on long branches in phylogenetic trees. This structure is revealed by excluding recombination events that mask the clonal descent of the genomes. Indeed, we show that genome-wide sweeps originate under a wide range of recombination rates in at least 66 taxa from 25 bacterial families. Estimated ages of divergence suggest that sweep clusters can spread globally within decades and that this process has occurred throughout human history. Sweep clusters are associated with different host conditions—such as age, colorectal cancer, inflammatory bowel diseases and type 2 diabetes—as an indication of their ecological differentiation. Our results reveal an evolutionary mechanism for the observation of stably inherited strains with differential associations and provide a theoretical foundation for analysing adaptation among microbial populations.
- Open Access
- 21 August 2025
- Published by Springer Nature in Progress in Orthodontics
- Vol. 26 (1) , 1
Correction: Exploring the impact of orthodontic appliances on the oral microbiome and inflammatory parameters
- 21 August 2025
- Published by Springer Nature in Progress in Orthodontics
- Vol. 26 (1) , 1
Open AccessCorrection: Exploring the impact of orthodontic appliances on the oral microbiome and inflammatory parameters
- Open Access
- 7 April 2025
- Published by Springer Nature in Progress in Orthodontics
- Vol. 26 (1) , 1-12
Exploring the impact of orthodontic appliances on the oral microbiome and inflammatory parameters
Background: The symbiotic relationship between the oral microbiome and the host immune system is a prerequisite of oral health. Disruptions to this system can be associated with the development of diseases like dental caries. Introducing orthodontic treatments, such as aligners and fixed appliances, might impact this microbial ecosystem. This study evaluated potential changes in salivary microbiome and the level of inflammatory marker myeloid-related protein 8/14 in patients undergoing orthodontic treatment with aligners or fixed appliances. Methods: Forty-eight patients were divided into two groups for treatment with fixed appliances or clear aligners. Unstimulated saliva samples were collected at baseline, three, and six months for microbiome analysis via 16 S rRNA sequencing and MRP-8/14 level measurement using ELISA. Results: Among 503 identified microbial species, no significant changes were noted in overall microbiome. A considerable increase of caries-relevant species could not be observed either. MRP-8/14 levels remained unchanged across treatments, indicating no alterations in the inflammatory level. Conclusion: Orthodontic treatment with fixed or removable appliances does not significantly alter the salivary microbiome or influence inflammation, suggesting that these interventions are unlikely to affect oral health negatively.
- 7 April 2025
- Published by Springer Nature in Progress in Orthodontics
- Vol. 26 (1) , 1-12
Open AccessExploring the impact of orthodontic appliances on the oral microbiome and inflammatory parameters
Background: The symbiotic relationship between the oral microbiome and the host immune system is a prerequisite of oral health. Disruptions to this system can be associated with the development of diseases like dental caries. Introducing orthodontic treatments, such as aligners and fixed appliances, might impact this microbial ecosystem. This study evaluated potential changes in salivary microbiome and the level of inflammatory marker myeloid-related protein 8/14 in patients undergoing orthodontic treatment with aligners or fixed appliances. Methods: Forty-eight patients were divided into two groups for treatment with fixed appliances or clear aligners. Unstimulated saliva samples were collected at baseline, three, and six months for microbiome analysis via 16 S rRNA sequencing and MRP-8/14 level measurement using ELISA. Results: Among 503 identified microbial species, no significant changes were noted in overall microbiome. A considerable increase of caries-relevant species could not be observed either. MRP-8/14 levels remained unchanged across treatments, indicating no alterations in the inflammatory level. Conclusion: Orthodontic treatment with fixed or removable appliances does not significantly alter the salivary microbiome or influence inflammation, suggesting that these interventions are unlikely to affect oral health negatively.
- Open Access
- 22 April 2024
- Published by Springer Nature in Infection
- Vol. 52 (5) , 1921-1930
High cure rates of Mycoplasma genitalium following empiric treatment with azithromycin alongside frequent detection of macrolide resistance in Austria
Background: Mycoplasma genitalium (MG) is an emerging sexually transmitted infection, often harboring resistance-associated mutations to azithromycin (AZM). Global surveillance has been mandated to tackle the burden caused by MG, yet no data are available for Austria. Thus, we aimed to investigate the prevalence of MG, disease characteristics, and treatment outcomes at the largest Austrian HIV—and STI clinic. Methods: All MG test results at the Medical University of Vienna from 02/2019 to 03/2022 were evaluated. Azithromycin resistance testing was implemented in 03/2021. Results: Among 2671 MG tests, 199 distinct and mostly asymptomatic (68%; 135/199) MG infections were identified, affecting 10% (178/1775) of all individuals. This study included 83% (1479/1775) men, 53% (940/1775) men who have sex with men (MSM), 31% (540/1754) HIV+, and 15% (267/1775) who were using HIV pre-exposure prophylaxis (PrEP). In logistic regression analysis, ‘MSM’ (aOR 2.55 (95% CI 1.65–3.92)), ‘use of PrEP’ (aOR 2.29 (95% CI 1.58–3.32)), and ‘history of syphilis’ (aOR 1.57 (95% CI 1.01–2.24) were independent predictors for MG infections. Eighty-nine percent (178/199) received treatment: 11% (21/178) doxycycline (2 weeks), 52% (92/178) AZM (5 days), and 37% ( 65/178) moxifloxacin (7–10 days) and 60% (106/178) had follow-up data available showing negative tests in 63% (5/8), 76% (44/58) and 85% (34/40), respectively. AZM resistance analysis was available for 57% (114/199)) and detected in 68% (78/114). Resistance-guided therapy achieved a cure in 87% (53/61), yet, empiric AZM-treatment (prior to 03/2021) cleared 68% (26/38). Conclusions: Mycoplasma genitalium was readily detected in this Austrian observational study, affected predominantly MSM and often presented as asymptomatic disease. We observed a worryingly high prevalence of AZM resistance mutations; however, empiric AZM treatment cleared twice as many MG infections as expected.
- 22 April 2024
- Published by Springer Nature in Infection
- Vol. 52 (5) , 1921-1930
Open AccessHigh cure rates of Mycoplasma genitalium following empiric treatment with azithromycin alongside frequent detection of macrolide resistance in Austria
Background: Mycoplasma genitalium (MG) is an emerging sexually transmitted infection, often harboring resistance-associated mutations to azithromycin (AZM). Global surveillance has been mandated to tackle the burden caused by MG, yet no data are available for Austria. Thus, we aimed to investigate the prevalence of MG, disease characteristics, and treatment outcomes at the largest Austrian HIV—and STI clinic. Methods: All MG test results at the Medical University of Vienna from 02/2019 to 03/2022 were evaluated. Azithromycin resistance testing was implemented in 03/2021. Results: Among 2671 MG tests, 199 distinct and mostly asymptomatic (68%; 135/199) MG infections were identified, affecting 10% (178/1775) of all individuals. This study included 83% (1479/1775) men, 53% (940/1775) men who have sex with men (MSM), 31% (540/1754) HIV+, and 15% (267/1775) who were using HIV pre-exposure prophylaxis (PrEP). In logistic regression analysis, ‘MSM’ (aOR 2.55 (95% CI 1.65–3.92)), ‘use of PrEP’ (aOR 2.29 (95% CI 1.58–3.32)), and ‘history of syphilis’ (aOR 1.57 (95% CI 1.01–2.24) were independent predictors for MG infections. Eighty-nine percent (178/199) received treatment: 11% (21/178) doxycycline (2 weeks), 52% (92/178) AZM (5 days), and 37% ( 65/178) moxifloxacin (7–10 days) and 60% (106/178) had follow-up data available showing negative tests in 63% (5/8), 76% (44/58) and 85% (34/40), respectively. AZM resistance analysis was available for 57% (114/199)) and detected in 68% (78/114). Resistance-guided therapy achieved a cure in 87% (53/61), yet, empiric AZM-treatment (prior to 03/2021) cleared 68% (26/38). Conclusions: Mycoplasma genitalium was readily detected in this Austrian observational study, affected predominantly MSM and often presented as asymptomatic disease. We observed a worryingly high prevalence of AZM resistance mutations; however, empiric AZM treatment cleared twice as many MG infections as expected.
- Open Access
- 4 March 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (3) , 517
Effect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects—A Pilot Study
Background: Antibiotic eye drops are frequently used in clinical practice. Due to the anatomical connection via the nasolacrimal duct, it seems possible that they have an influence on the nasal/pharyngeal microbiome. This was investigated by using two different commonly used antibiotic eye drops. Methods: 20 subjects were randomized to four groups of five subjects receiving eye drops containing gentamicin, ciprofloxacin, or, as controls, unpreserved povidone or benzalkonium chloride-preserved povidone. Nasal and pharyngeal swabs were performed before and after the instillation period. Swabs were analyzed by Illumina next-generation sequencing (NGS)-based 16S rRNA analysis. Bacterial culture was performed on solid media, and bacterial isolates were identified to the species level by MALDI-TOF MS. Species-dependent antimicrobial susceptibility testing was performed using single isolates and pools of isolates. Results: Bacterial richness in the nose increased numerically from 163 ± 30 to 243 ± 100 OTUs (gentamicin) and from 114 ± 17 to 144 ± 45 OTUs (ciprofloxacin). Phylogenetic diversity index (pd) of different bacterial strains in the nasal microbiome increased from 12.4 ± 1.0 to 16.9 ± 5.6 pd (gentamicin) and from 10.2 ± 1.4 to 11.8 ± 3.1 pd (ciprofloxacin). Unpreserved povidone eye drops resulted in minimal changes in bacterial counts. Preservative-containing povidone eye drops resulted in no change. A minor increase (1–2-fold) in the minimal inhibitory concentration (MIC) was observed in single streptococcal isolates. Conclusions: Antibiotic eye drops could affect the nasal microbiome. After an instillation period of seven days, an increase in the diversity and richness of bacterial strains in the nasal microbiome was observed.
- 4 March 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (3) , 517
Open AccessEffect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects—A Pilot Study
Background: Antibiotic eye drops are frequently used in clinical practice. Due to the anatomical connection via the nasolacrimal duct, it seems possible that they have an influence on the nasal/pharyngeal microbiome. This was investigated by using two different commonly used antibiotic eye drops. Methods: 20 subjects were randomized to four groups of five subjects receiving eye drops containing gentamicin, ciprofloxacin, or, as controls, unpreserved povidone or benzalkonium chloride-preserved povidone. Nasal and pharyngeal swabs were performed before and after the instillation period. Swabs were analyzed by Illumina next-generation sequencing (NGS)-based 16S rRNA analysis. Bacterial culture was performed on solid media, and bacterial isolates were identified to the species level by MALDI-TOF MS. Species-dependent antimicrobial susceptibility testing was performed using single isolates and pools of isolates. Results: Bacterial richness in the nose increased numerically from 163 ± 30 to 243 ± 100 OTUs (gentamicin) and from 114 ± 17 to 144 ± 45 OTUs (ciprofloxacin). Phylogenetic diversity index (pd) of different bacterial strains in the nasal microbiome increased from 12.4 ± 1.0 to 16.9 ± 5.6 pd (gentamicin) and from 10.2 ± 1.4 to 11.8 ± 3.1 pd (ciprofloxacin). Unpreserved povidone eye drops resulted in minimal changes in bacterial counts. Preservative-containing povidone eye drops resulted in no change. A minor increase (1–2-fold) in the minimal inhibitory concentration (MIC) was observed in single streptococcal isolates. Conclusions: Antibiotic eye drops could affect the nasal microbiome. After an instillation period of seven days, an increase in the diversity and richness of bacterial strains in the nasal microbiome was observed.
- Open Access
- 14 February 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (3) , 724
Correction: Disturbances in microbial skin recolonization and cutaneous immune response following allogeneic stem cell transfer
- 14 February 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (3) , 724
Open AccessCorrection: Disturbances in microbial skin recolonization and cutaneous immune response following allogeneic stem cell transfer
- Open Access
- 17 January 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (2) , 129
Candida auris in Austria—What Is New and What Is Different
Candida auris is a novel and emerging pathogenic yeast which represents a serious global health threat. Since its first description in Japan 2009, it has been associated with large hospital outbreaks all over the world and is often resistant to more than one antifungal drug class. To date, five C. auris isolates have been detected in Austria. Morphological characterization and antifungal susceptibility profiles against echinocandins, azoles, polyenes and pyrimidines, as well as the new antifungals ibrexafungerp and manogepix, were determined. In order to assess pathogenicity of these isolates, an infection model in Galleria mellonella was performed and whole genome sequencing (WGS) analysis was conducted to determine the phylogeographic origin. We could characterize four isolates as South Asian clade I and one isolate as African clade III. All of them had elevated minimal inhibitory concentrations to at least two different antifungal classes. The new antifungal manogepix showed high in vitro efficacy against all five C. auris isolates. One isolate, belonging to the African clade III, showed an aggregating phenotype, while the other isolates belonging to South Asian clade I were non-aggregating. In the Galleria mellonella infection model, the isolate belonging to African clade III exhibited the lowest in vivo pathogenicity. As the occurrence of C. auris increases globally, it is important to raise awareness to prevent transmission and hospital outbreaks.
- 17 January 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (2) , 129
Open AccessCandida auris in Austria—What Is New and What Is Different
Candida auris is a novel and emerging pathogenic yeast which represents a serious global health threat. Since its first description in Japan 2009, it has been associated with large hospital outbreaks all over the world and is often resistant to more than one antifungal drug class. To date, five C. auris isolates have been detected in Austria. Morphological characterization and antifungal susceptibility profiles against echinocandins, azoles, polyenes and pyrimidines, as well as the new antifungals ibrexafungerp and manogepix, were determined. In order to assess pathogenicity of these isolates, an infection model in Galleria mellonella was performed and whole genome sequencing (WGS) analysis was conducted to determine the phylogeographic origin. We could characterize four isolates as South Asian clade I and one isolate as African clade III. All of them had elevated minimal inhibitory concentrations to at least two different antifungal classes. The new antifungal manogepix showed high in vitro efficacy against all five C. auris isolates. One isolate, belonging to the African clade III, showed an aggregating phenotype, while the other isolates belonging to South Asian clade I were non-aggregating. In the Galleria mellonella infection model, the isolate belonging to African clade III exhibited the lowest in vivo pathogenicity. As the occurrence of C. auris increases globally, it is important to raise awareness to prevent transmission and hospital outbreaks.
- 12 October 2022
- Published by Springer Nature in Leukemia
- Vol. 36 (11) , 2705-2714
Disturbances in microbial skin recolonization and cutaneous immune response following allogeneic stem cell transfer
The composition of the gut microbiome influences the clinical course after allogeneic hematopoietic stem cell transplantation (HSCT), but little is known about the relevance of skin microorganisms. In a single-center, observational study, we recruited a cohort of 50 patients before undergoing conditioning treatment and took both stool and skin samples up to one year after HSCT. We could confirm intestinal dysbiosis following HSCT and report that the skin microbiome is likewise perturbed in HSCT-recipients. Overall bacterial colonization of the skin was decreased after conditioning. Particularly patients that developed acute skin graft-versus-host disease (aGVHD) presented with an overabundance of Staphylococcus spp. In addition, a loss in alpha diversity was indicative of aGVHD development already before disease onset and correlated with disease severity. Further, co-localization of CD45+ leukocytes and staphylococci was observed in the skin of aGVHD patients even before disease development and paralleled with upregulated genes required for antigen-presentation in mononuclear phagocytes. Overall, our data reveal disturbances of the skin microbiome as well as cutaneous immune response in HSCT recipients with changes associated with cutaneous aGVHD.
- 12 October 2022
- Published by Springer Nature in Leukemia
- Vol. 36 (11) , 2705-2714
Disturbances in microbial skin recolonization and cutaneous immune response following allogeneic stem cell transfer
The composition of the gut microbiome influences the clinical course after allogeneic hematopoietic stem cell transplantation (HSCT), but little is known about the relevance of skin microorganisms. In a single-center, observational study, we recruited a cohort of 50 patients before undergoing conditioning treatment and took both stool and skin samples up to one year after HSCT. We could confirm intestinal dysbiosis following HSCT and report that the skin microbiome is likewise perturbed in HSCT-recipients. Overall bacterial colonization of the skin was decreased after conditioning. Particularly patients that developed acute skin graft-versus-host disease (aGVHD) presented with an overabundance of Staphylococcus spp. In addition, a loss in alpha diversity was indicative of aGVHD development already before disease onset and correlated with disease severity. Further, co-localization of CD45+ leukocytes and staphylococci was observed in the skin of aGVHD patients even before disease development and paralleled with upregulated genes required for antigen-presentation in mononuclear phagocytes. Overall, our data reveal disturbances of the skin microbiome as well as cutaneous immune response in HSCT recipients with changes associated with cutaneous aGVHD.
- 23 June 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (7) , e1719-e1726
Apparent Intracellular Helicobacter pylori Detected by Immunohistochemistry: The Missing Link in Eradication Failure
Helicobacter (H.) pylori is primarily an extracellularly living bacterium. However, seemingly intracellular occurrence can often be detected by immunohistochemical stains. Considering antimicrobial resistance, we investigated the impact of the apparent intracellular H. pylori (aiHp) on treatment failure of first-line triple therapies. Gastric biopsies of 814 H. pylori infected patients naïve for treatment were analyzed before and after eradication therapy by immunohistochemistry. Thereof, 373 received treatment consisting of amoxicillin, clarithromycin and PPI (AC/PPI). Availability of PCR-based clarithromycin susceptibility test results from pre-treatment gastric biopsies was a pre-condition for matching 52 aiHp to 52 non-aiHp cases within the AC/PPI-group. AiHp were detected mostly in low counts predominantly in corpus, rarely in antrum biopsies (95.2% vs. 24.6%); they were found in 497 (61%) of all patients and in 192 of 373 patients (51.5%) in the AC/PPI-group. The eradication rate in aiHp vs. non-aiHp cases was 44.4% vs. 72.9% in the entire sample and 45.3% vs. 66.8% in the AC/PPI-group. Among the 104 paired patients, respective values were 46.2% vs. 78.8%; in clarithromycin susceptible cases 60.6% vs. 91.9%. Both aiHp and resistance to clarithromycin proved to be highly significant (p≤0.001) and independent predictors of eradication failure. Twelve of 13 aiHp cases with a clarithromycin sensitive strain, who failed eradication, developed resistance to the antibiotic. AiHp found by immunohistochemical staining especially in corpus biopsies proved to be a risk factor for failure of first-line triple therapies; occurrence of aiHp should be considered with regard to therapy options.
- 23 June 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (7) , e1719-e1726
Apparent Intracellular Helicobacter pylori Detected by Immunohistochemistry: The Missing Link in Eradication Failure
Helicobacter (H.) pylori is primarily an extracellularly living bacterium. However, seemingly intracellular occurrence can often be detected by immunohistochemical stains. Considering antimicrobial resistance, we investigated the impact of the apparent intracellular H. pylori (aiHp) on treatment failure of first-line triple therapies. Gastric biopsies of 814 H. pylori infected patients naïve for treatment were analyzed before and after eradication therapy by immunohistochemistry. Thereof, 373 received treatment consisting of amoxicillin, clarithromycin and PPI (AC/PPI). Availability of PCR-based clarithromycin susceptibility test results from pre-treatment gastric biopsies was a pre-condition for matching 52 aiHp to 52 non-aiHp cases within the AC/PPI-group. AiHp were detected mostly in low counts predominantly in corpus, rarely in antrum biopsies (95.2% vs. 24.6%); they were found in 497 (61%) of all patients and in 192 of 373 patients (51.5%) in the AC/PPI-group. The eradication rate in aiHp vs. non-aiHp cases was 44.4% vs. 72.9% in the entire sample and 45.3% vs. 66.8% in the AC/PPI-group. Among the 104 paired patients, respective values were 46.2% vs. 78.8%; in clarithromycin susceptible cases 60.6% vs. 91.9%. Both aiHp and resistance to clarithromycin proved to be highly significant (p≤0.001) and independent predictors of eradication failure. Twelve of 13 aiHp cases with a clarithromycin sensitive strain, who failed eradication, developed resistance to the antibiotic. AiHp found by immunohistochemical staining especially in corpus biopsies proved to be a risk factor for failure of first-line triple therapies; occurrence of aiHp should be considered with regard to therapy options.